TRAF1/C5 but Not PTPRC Variants Are Potential Predictors of Rheumatoid Arthritis Response to Anti-Tumor Necrosis Factor Therapy
- PMID: 25834819
- PMCID: PMC4365300
- DOI: 10.1155/2015/490295
TRAF1/C5 but Not PTPRC Variants Are Potential Predictors of Rheumatoid Arthritis Response to Anti-Tumor Necrosis Factor Therapy
Abstract
Background: The aim of our work was to replicate, in a Southern European population, the association reported in Northern populations between PTPRC locus and response to anti-tumor necrosis factor (anti-TNF) treatment in rheumatoid arthritis (RA). We also looked at associations between five RA risk alleles and treatment response.
Methods: We evaluated associations between anti-TNF treatment responses assessed by DAS28 change and by EULAR response at six months in 383 Portuguese patients. Univariate and multivariate linear and logistic regression analyses were performed. In a second step to confirm our findings, we pooled our population with 265 Spanish patients.
Results: No association was found between PTPRC rs10919563 allele and anti-TNF treatment response, neither in Portuguese modeling for several clinical variables nor in the overall population combining Portuguese and Spanish patients. The minor allele for RA susceptibility, rs3761847 SNP in TRAF1/C5 region, was associated with a poor response in linear and logistic univariate and multivariate regression analyses. No association was observed with the other allellic variants. Results were confirmed in the pooled analysis.
Conclusion: This study did not replicate the association between PTPRC and the response to anti-TNF treatment in our Southern European population. We found that TRAF1/C5 risk RA variants potentially influence anti-TNF treatment response.
Similar articles
-
Single nucleotide polymorphisms at the TRAF1/C5 locus are associated with rheumatoid arthritis in a Han Chinese population.BMC Med Genet. 2011 Apr 14;12:53. doi: 10.1186/1471-2350-12-53. BMC Med Genet. 2011. PMID: 21492465 Free PMC article.
-
Replication of association of the PTPRC gene with response to anti-tumor necrosis factor therapy in a large UK cohort.Arthritis Rheum. 2012 Mar;64(3):665-70. doi: 10.1002/art.33381. Arthritis Rheum. 2012. PMID: 21952740 Free PMC article.
-
Associations between PTPRC rs10919563 A/G and FCGR2A R131H polymorphisms and responsiveness to TNF blockers in rheumatoid arthritis: a meta-analysis.Rheumatol Int. 2016 Jun;36(6):837-44. doi: 10.1007/s00296-016-3476-5. Epub 2016 Apr 13. Rheumatol Int. 2016. PMID: 27074847 Review.
-
Rheumatoid arthritis risk allele PTPRC is also associated with response to anti-tumor necrosis factor alpha therapy.Arthritis Rheum. 2010 Jul;62(7):1849-61. doi: 10.1002/art.27457. Arthritis Rheum. 2010. PMID: 20309874 Free PMC article. Clinical Trial.
-
A single tumour necrosis factor haplotype influences the response to adalimumab in rheumatoid arthritis.Ann Rheum Dis. 2008 Apr;67(4):478-84. doi: 10.1136/ard.2007.074104. Epub 2007 Aug 2. Ann Rheum Dis. 2008. PMID: 17673491 Free PMC article. Review.
Cited by 7 articles
-
Association of TRAF1/C5 Locus Polymorphisms with Epilepsy and Clinical Traits in Mexican Patients with Neurocysticercosis.Infect Immun. 2019 Nov 18;87(12):e00347-19. doi: 10.1128/IAI.00347-19. Print 2019 Dec. Infect Immun. 2019. PMID: 31570557 Free PMC article.
-
TRAF1 Signaling in Human Health and Disease.Front Immunol. 2018 Dec 18;9:2969. doi: 10.3389/fimmu.2018.02969. eCollection 2018. Front Immunol. 2018. PMID: 30619326 Free PMC article. Review.
-
TRAF molecules in inflammation and inflammatory diseases.Curr Pharmacol Rep. 2018 Feb;4(1):64-90. doi: 10.1007/s40495-017-0117-y. Epub 2017 Dec 20. Curr Pharmacol Rep. 2018. PMID: 29527458 Free PMC article.
-
Systematic review and meta-analysis: pharmacogenetics of anti-TNF treatment response in rheumatoid arthritis.Pharmacogenomics J. 2017 Oct;17(5):403-411. doi: 10.1038/tpj.2017.26. Epub 2017 Jun 13. Pharmacogenomics J. 2017. PMID: 28607508 Free PMC article. Review.
-
Genetics of rheumatoid arthritis susceptibility, severity, and treatment response.Semin Immunopathol. 2017 Jun;39(4):395-408. doi: 10.1007/s00281-017-0630-4. Epub 2017 May 29. Semin Immunopathol. 2017. PMID: 28555384 Free PMC article. Review.
References
-
- Maini R., St Clair E. W., Breedveld F., et al. Infliximab (chimeric anti-tumour necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. The Lancet. 1999;354(9194):1932–1939. doi: 10.1016/s0140-6736(99)05246-0. - DOI - PubMed
-
- Hetland M. L., Christensen I. J., Tarp U., et al. Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry. Arthritis and Rheumatism. 2010;62(1):22–32. doi: 10.1002/art.27227. - DOI - PubMed
-
- Hyrich K. L., Watson K. D., Silman A. J., Symmons D. P. M. Predictors of response to anti-TNF-α therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Rheumatology. 2006;45(12):1558–1565. doi: 10.1093/rheumatology/kel149. - DOI - PubMed
Publication types
MeSH terms
Substances
Grant support
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous
